• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Skin Toxicity Vinca Alkaloid Calcium Folinate Extravasation Injury Cancer Chemotherapeutic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Choy DS: Effective treatment of inadvertent intramuscular administration of vincristine. JAMA 241: 695, 1979.PubMedCrossRefGoogle Scholar
  2. [2]
    Bellone JD: Treatment of vincristine extravasation. JAMA 245: 343, 1981.PubMedCrossRefGoogle Scholar
  3. [3]
    Bertelli G, Dini D, Forno GB, et al: Hyaluronidase as an antidote to extravasation of vnca alkaloids: clinical results. J Cancer Res Clin Oncol 120: 505–506, 1994.PubMedCrossRefGoogle Scholar
  4. [4]
    Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74: 113–120, 1985.PubMedGoogle Scholar
  5. [5]
    Comas D, Mateu J: Treatment of extravasation of both doxorubicin and vincristine administration in a y-site infusion. Ann Pharmacother 30: 244–246, 1996.PubMedGoogle Scholar
  6. [6]
    Webster PJ, D Souza D: Extravasation of epirubicin/vincristine and ifosfamide/mesna from a central venous catheter. J Oncol Pharm Practice 1: 41–44, 1995.Google Scholar
  7. [7]
    Chait LA, Dinner MI: Ulceration caused by cytotoxic drugs. S Afr Med J 49: 1935–1936, 1975.PubMedGoogle Scholar
  8. [8]
    James DH, George P: Vincristine in children with malignant solid tumors. J Pediatr 64: 534–541, 1964.PubMedCrossRefGoogle Scholar
  9. [9]
    Germain BS, Houlihan N, D’Amato S: Dimethyl sulfoxide therapy in the treatment of vesicant extravasation. J Intrav Nurs 17: 261–266, 1994.Google Scholar
  10. [10]
    Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.Google Scholar
  11. [11]
    Larson DL: Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796–1799, 1982.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [12]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  2. [13]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Vincristin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 3: 44–45, 1998.Google Scholar
  3. [14]
    Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.Google Scholar
  4. [15]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  5. [16]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  6. [17]
    Berdel WE, Schmoll HJ, Büchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.Google Scholar
  7. [18]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  8. [19]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  9. [20]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  10. [21]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  11. [22]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: 42–44, 1997.Google Scholar
  12. [23]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  13. [24]
    Bristol-Myers Squibb, personal communication, November 1998.Google Scholar
  14. [25]
    Summary of product characteristics Oncovin (Austria), Eli Lilly, May 1995.Google Scholar
  15. [26]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar

Further reading

  1. Barr RD, Sertic J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Br J Cancer 44: 267–269, 1981.PubMedCrossRefGoogle Scholar
  2. Buchanan GR, Buchsbaum HJ, O’Banion K, et al: Extravasation of dactinomycin, vincristine, and cisplatin: studies in an animal model. Med Pediatr Oncol 13: 375–380, 1985.PubMedCrossRefGoogle Scholar
  3. Ignoffo RJ, Tomlin W, Rubinstein E, et al: A model for skin toxicity of antineoplastic drugs: doxorubicin (DOX), mitomycin-C (MMC), and vincristine (VCR). Clin Res 29: 437A, 1981.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations